Cargando…

Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer

Patient: Male, 37 Final Diagnosis: Lung adenocarcinoma Symptoms: Cough Medication: — Clinical Procedure: — Specialty: Oncology OBJECTIVE: Unusual setting of medical care BACKGROUND: The treatment of locally advanced non-small cell lung cancer involves a combination of chemotherapy, surgery, and radi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dumont, Delphine, Dô, Pascal, Lerouge, Delphine, Planchard, Gaëtane, Riffet, Marc, Dubos-Arvis, Catherine, Danhier, Serge, Gervais, Radj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567855/ https://www.ncbi.nlm.nih.gov/pubmed/28808224 http://dx.doi.org/10.12659/AJCR.903528

Ejemplares similares

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
por: Lesueur, Paul, et al.
Publicado: (2018)

Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients
por: Lasnon, Charline, et al.
Publicado: (2013)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
por: Césaire, Mathieu, et al.
Publicado: (2022)

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer
por: Xie, Xiao-Hong, et al.
Publicado: (2021)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

I Gave Up—Why Carla Markham Got off the Couch
Publicado: (1968)

Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test
por: Dupont, Benoît, et al.
Publicado: (2014)

Hormonal Effects on Nodular GAVE
por: Brijbassie, Alan, et al.
Publicado: (2013)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
por: Nagumo, Yoshiyuki, et al.
Publicado: (2018)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

How oxygen gave rise to eukaryotic sex
por: Hörandl, Elvira, et al.
Publicado: (2018)

Ionic liquids IIIA
por: Rogers, Robin D, et al.
Publicado: (2005)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab
por: Serrier, Julien, et al.
Publicado: (2023)

The Director General gave an arbitration in favor of the staff members
por: staff Association
Publicado: (2022)

Planting? or Implantation? Who First Gave This Operation to the Profession?
por: Robinson, W. H.
Publicado: (1898)

'Dental nursing gave me a kick start'
por: Mehmood, Aisha
Publicado: (2023)

Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
por: Chen, Caroline Y., et al.
Publicado: (2021)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
por: Wang, Hongming, et al.
Publicado: (2023)

Crizotinib: A comprehensive review
por: Sahu, Arvind, et al.
Publicado: (2013)

Crizotinib: Pneumonitis: case report
Publicado: (2021)

Optical fiber telecommunications IIIA
Publicado: (1997)

From hypertransaminasemia to mucopolysaccharidosis IIIA
por: Krawiec, Paulina, et al.
Publicado: (2014)

Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study
por: Huang, Zhangfeng, et al.
Publicado: (2021)

Use of crizotinib as neoadjuvant therapy for non‐small cell lung cancers patient with ROS1 rearrangement: A case report
por: Zhao, Shikang, et al.
Publicado: (2021)

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
por: Hui, Zhenzhen, et al.
Publicado: (2022)

Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy
por: Qu, Chenghao, et al.
Publicado: (2022)

Efficacy and outcome analysis: Combination of Endostar and chemotherapy as a neoadjuvant treatment of stage IIIA/IIIB squamous cell lung cancer
por: Cao, Feiyi, et al.
Publicado: (2023)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2021)

Baby Genomics: Tracing the Evolutionary Changes That Gave Rise to Placentation
por: Hao, Yue, et al.
Publicado: (2020)

Stoner Ferromagnetism in Hole-Doped CuM(IIIA)O(2) with M(IIIA) = Al, Ga, and In
por: Iordanidou, Konstantina, et al.
Publicado: (2021)

Crizotinib targets in glioblastoma stem cells
por: Junca, Audelaure, et al.
Publicado: (2017)

Crizotinib-induced Rectal Perforation with Abscess
por: Yanagisawa, Asako, et al.
Publicado: (2017)

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
por: Shin, Sumin, et al.
Publicado: (2020)

The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer
por: Wang, Jiangfeng, et al.
Publicado: (2021)

Effects of Neoadjuvant Therapy After the Initial Assessment of Operability in Patients with Borderline Operable and Inoperable Stage IIIA Non-small Lung Cancer
por: Pilav, Ilijaz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e4lmks5q3aed9vpggpuh5672ri